Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 TrialSumanta K. Pal,Petros Grivas,Shilpa Gupta,Nazli Dizman,Zeynep Zengin,Begona P. Valderrama,Alejo Rodriguez-Vida,Florian Roghmann, Elena Sevillano Fernandez,Surena F. Matin,Yohann Loriot,Srikala S. Sridhar,Guru Sonpavde,Mark T. Fleming,Seth P. Lerner,Joaquim Bellmunt,Viraj Master,Abhishek Tripathi, Kim Davis, David van VeenhuyzenEuropean Urology（2024）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
